Add BrightSurf on Google Email

Autologous stem cell transplants do not improve survival for mantle cell lymphoma patients with undetectable MRD, clinical trial shows

A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.

SourceECOG-ACRIN Cancer Research Group·TypeRandomized controlled/clinical trial·DateDec 10, 2024

ASH 2024: Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.

SourceUniversity of Miami Miller School of Medicine·JournalThe Lancet Haematology·DateDec 8, 2024

Fred Hutch at ASH: Plenary session on socioeconomic barriers to transplant, new leukemia treatments and phasing out ‘cumbersome’ urine test

Researchers at Fred Hutchinson Cancer Center are addressing socioeconomic barriers to access to life-saving transplants for blood disorders. New leukemia treatment regimens have shown promise in clinical trials, while a prediction model highlights improved survivorship and quality of life outcomes for older patients after transplant.

New CAR-T cell therapy gives hope for patients with aggressive blood cancer

A new chimeric antigen receptor T cell (CAR-T) therapy called obe-cel has delivered promising results in treating patients with an aggressive blood cancer. The treatment reduced immune toxicity and persisted for longer in patients, overcoming two common limitations of earlier CAR-T cell therapies.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 29, 2024

Stand Up to Cancer collaborates with Johnson & Johnson to explore targeted therapies for rare disease linked to blood cancers

A new research project will test a combination of two targeted therapies, teclistamab and daratumumab, to treat AL amyloidosis, a rare disease affecting approximately 4,500 people annually in the U.S. The study aims to leverage previous findings from multiple myeloma to expand understanding of this treatment option.

SourceStand Up To Cancer·TypeNews article·DateNov 11, 2024

'Black box' of stem cell transplants opened in world-first blood study

Researchers tracked the long-term dynamics of transplanted stem cells in patients' bodies up to three decades post-transplant. They found that younger donors produce more vital stem cells, while older donors experience reduced immunity and higher relapse risk. The study provides new insights into donor selection and transplant success.

SourceWellcome Trust Sanger Institute·JournalNature·TypeObservational study·DateOct 30, 2024

Double strike against blood cancer

Scientists have identified a molecular mechanism that eliminates defective cells during faulty cell division, shedding new light on the fundamental processes involved. The discovery could lead to more effective treatments for blood cancer by targeting cells with multiple centrosomes, which are a hallmark of disrupted division.

SourceCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences·JournalScience Advances·TypeExperimental study·DateOct 30, 2024

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment across US and Canada

The myeloMATCH program offers a portfolio of biomarker-driven treatment trials to accelerate precision medicine in myeloid malignancies. Patients can enroll in clinical trials throughout their cancer treatment journey, with test results returned quickly to assign them to the most appropriate trial.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateOct 23, 2024

USC Stem Cell mouse study sheds light on the secret to maintaining a youthful immune system

A USC Stem Cell mouse study identifies a small subset of blood stem cells as the primary driver of immune aging. The researchers found that this subset overproduces innate immune cells, leading to an age-associated imbalance and increased disease risk. By targeting this subset, the study suggests a potential therapy to delay immune agi...

SourceKeck School of Medicine of USC·JournalCellular and Molecular Immunology·TypeExperimental study·DateOct 23, 2024

How blood cancer cells rewire to evade drug treatment

Researchers found that blood cancer cells rewired their gene regulatory networks to evade drug treatment in Acute Myeloid Leukemia (AML), disrupting normal differentiation and growth. The study identified key findings, including changes in open chromatin regions and the loss of binding of RUNX1 and AP-1 transcription factors.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateOct 23, 2024

Survival gap eliminated for Black cord blood recipients with blood cancers, study finds

A retrospective analysis of over 2,600 patients found that Black children were more likely to suffer severe graft-versus-host disease but overall survival rates improved across all racial groups. The study suggests that cord blood transplants are a vital lifeline for many patients and improve care for those without a matched donor.

SourceUniversity of Virginia Health System·JournalTransplantation and Cellular Therapy·DateOct 1, 2024

Scientists discover how the body's killer cells attack cancer

Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.

SourceUniversity of Southampton·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 28, 2024

Moffitt Consortium study answers questions about long-term survivorship following CAR T treatment

The study found that 29% of patients experienced progression-free survival at five years and 40% achieved overall survival. However, important survivorship issues were identified, including nonrelapse mortality rates of 16.2%, with over half occurring beyond two years post-treatment.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalJournal of Clinical Oncology·TypeObservational study·DateAug 5, 2024

Fighting leukemia by targeting its stem cells

Researchers identified genetic and metabolic characteristics of leukaemic stem cells, including a specific iron utilisation process that can be blocked to kill these cells without harming healthy ones. This breakthrough paves the way for new therapeutic strategies to combat leukemia.

SourceUniversité de Genève·JournalScience Translational Medicine·TypeNews article·DateJul 24, 2024

Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia

A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.

SourceOsaka Metropolitan University·JournalBlood Cancer Journal·TypeObservational study·DateJul 18, 2024

New study finds cell donor’s socioeconomic status shapes cancer treatment outcomes

A new study published in PNAS reveals that cancer patients who receive hematopoietic cell transplants from donors with lower socioeconomic status experience reduced overall survival and increased transplant-related mortality. The research highlights the profound impact of social inequality on health outcomes, particularly in cancer care.

SourceUniversity of Minnesota Medical School·JournalProceedings of the National Academy of Sciences·TypeData/statistical analysis·DateJul 17, 2024

Pilot study in JNCCN explores new approach for reducing anxiety and improving quality of life after stem cell transplantation

Researchers developed a nine-week, phone-delivered positive psychology program called PATH to improve psychological well-being in blood cancer patients. The intervention had promising effects on patient-reported outcomes, with high participation and completion rates.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJun 11, 2024

ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies

A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.

Fred Hutch at ASCO: Progress in treating metastatic cancer, hospice access for cancer patients, use of machine learning with CAR T-cell therapy

Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.

Genes driving age-related blood cell mutations uncovered

Scientists have discovered 17 new genes involved in clonal haematopoiesis, a process associated with ageing linked to increased risks of blood cancers. The findings highlight the clinical significance of these genes in driving mutant blood cell clones, offering new avenues for studying disease development and promoting healthier ageing.

SourceWellcome Trust Sanger Institute·JournalNature Genetics·TypeObservational study·DateMay 14, 2024

A third Covid vaccine dose improves defence for some clinically extremely vulnerable patients

A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.

SourceUniversity of Birmingham·JournalThe Lancet Rheumatology·TypeRandomized controlled/clinical trial·DateMay 8, 2024

Testing for residual cancer cells before blood cell transplant therapy is important and practical, new study finds

A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.

SourceVirginia Tech·JournalJAMA Oncology·TypeData/statistical analysis·DateMay 2, 2024

One-two punch treatment delivers blood cancer knockout

A novel combination of two existing drugs has been discovered to eradicate AML cancer cells in lab-based tests, offering hope for patients diagnosed annually with the disease. The treatment, pairing venetoclax with a STING agonist, showed high promise in AML samples driven by a mutated p53 protein, a type of AML generally harder to treat.

SourceWalter and Eliza Hall Institute·JournalCancer Cell·TypeObservational study·DateApr 30, 2024

Chinese Medical Journal Review highlights novel pathogenic mechanisms and therapeutic potentials in cancer treatment targeting internal N6-methyladenosine and N7-methylguanine

Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.

SourceCactus Communications·JournalChinese Medical Journal·TypeLiterature review·DateApr 10, 2024